The Beauty Health Company (SKIN) Key Metrics
SKIN valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $68.7M
- Enterprise value
- $248.6M
- P/E (TTM)
- —
- Forward P/E
- 106.4
- PEG ratio
- 0.93
- Price / sales
- 0.2 10-yr median 1.0
- Price / book
- 1.6 10-yr median 5.6
- EV / EBITDA
- 9.6 10-yr median 18.8
- Dividend yield
- —
- Beta
- 1.05
SKIN key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsSKIN valuation Price multiples at each fiscal year-end price.
Price / sales−7.4%
0.6
2025 · hover or tap a bar for each year
20182025
Price / book−29.4%
3.1
2025 · hover or tap a bar for each year
20182025
EV / EBITDA−70.4%
8.6
2025 · hover or tap a bar for each year
20182025
Price / free cash flow−75.9%
5.8
2025 · hover or tap a bar for each year
20182025
Free cash flow yield+13.0 pts
17.1%
2025 · hover or tap a bar for each year
20182025
SKIN returns How much profit the business earns on the capital it uses.
Return on equity+35.5 pts
−16.9%
2025 · hover or tap a bar for each year
20182025
Return on invested capital+12.7 pts
−7.2%
2025 · hover or tap a bar for each year
20182025
Return on assets+2.0 pts
−1.6%
2025 · hover or tap a bar for each year
20182025
Free cash flow margin+8.0 pts
10.7%
2025 · hover or tap a bar for each year
20182025
Asset turnover+22.6%
0.51
2025 · hover or tap a bar for each year
20182025
SKIN per-share figures Results divided by the shares outstanding at year-end.
Revenue per share−5.6%
$44.30
2025 · hover or tap a bar for each year
20182025
Earnings per share
−$1.40
2025 · hover or tap a bar for each year
20182025
Free cash flow per share+263.1%
$4.76
2025 · hover or tap a bar for each year
20182025
Book value per share+23.8%
$9.00
2025 · hover or tap a bar for each year
20182025
Shares outstanding−4.7%
6.8M
2025 · hover or tap a bar for each year
20182025
SKIN financial health Debt, liquidity and how easily interest is covered.
Debt / equity−43.5%
6.20
2025 · hover or tap a bar for each year
20182025
Net debt−$52.1M
$146.0M
2025 · hover or tap a bar for each year
20182025
Net debt / EBITDA−9.85
3.77
2025 · hover or tap a bar for each year
20182025
Current ratio−76.3%
1.66
2025 · hover or tap a bar for each year
20182025
Interest coverage
-1.1
2025 · hover or tap a bar for each year
20182025
Debt / assets−8.6%
0.76
2025 · hover or tap a bar for each year
20182025
SKIN efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding−14 days
31 days
2025 · hover or tap a bar for each year
20182025
Days of inventory+12 days
205 days
2025 · hover or tap a bar for each year
20182025
Days payables outstanding−14 days
66 days
2025 · hover or tap a bar for each year
20182025
Cash conversion cycle+12 days
171 days
2025 · hover or tap a bar for each year
20182025
Capex / revenue−0.3 pts
1.7%
2025 · hover or tap a bar for each year
20182025
Dividends + buybacks / FCF−21.0 pts
0.0%
2025 · hover or tap a bar for each year
20182025
SKIN valuation history
Fiscal year-endToday8-year median
SKIN returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
SKIN debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
SKIN cash returned to shareholders
DividendsBuybacksFree cash flow
SKIN price vs earnings per share
Share price at year-endEPS (right axis)
SKIN key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Market capitalization | $188.8M | $226.6M | $409.5M | $1.35B | — | $387.9M | — | — |
| Enterprise value | $334.8M | $424.7M | $638.8M | $1.54B | — | $594.9M | — | — |
| P/E ratio | — | — | — | 30.6 | — | — | — | — |
| Price / sales | 0.6 | 0.7 | 1.0 | 3.7 | — | 3.3 | — | — |
| Price / book | 3.1 | 4.4 | 6.9 | 8.1 | — | — | — | — |
| Price / free cash flow | 5.8 | 24.3 | 47.1 | — | — | — | — | — |
| Price / operating cash flow | 5.0 | 14.0 | 18.8 | — | — | — | — | — |
| EV / sales | 1.1 | 1.3 | 1.6 | 4.2 | — | 5.0 | — | — |
| EV / EBITDA | 8.6 | 29.2 | — | 18.8 | — | — | — | — |
| EV / free cash flow | 10.4 | 45.5 | 73.4 | — | — | — | — | — |
| Earnings yield | −5.0% | −12.8% | −24.4% | 3.3% | — | −7.5% | — | — |
| Free cash flow yield | 17.1% | 4.1% | 2.1% | −9.2% | — | −4.2% | — | — |
| Dividend yield | — | — | — | — | — | 0.1% | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | 0.9% | 7.9% | 11.8% | — | 0.1% | — | — |
| Share price at fiscal year-end | $27.80 | $31.80 | $62.20 | $182.00 | $483.20 | $226.20 | — | — |
| Per share | ||||||||
| Revenue per share | $44.30 | $46.92 | $60.45 | $49.27 | — | $69.46 | $103.70 | $17.91 |
| Earnings per share | −$1.40 | −$4.08 | −$15.21 | $5.96 | — | −$17.01 | −$1.02 | −$0.05 |
| Operating cash flow per share | $5.52 | $2.26 | $3.30 | −$14.36 | — | −$7.25 | $1.08 | −$0.14 |
| Free cash flow per share | $4.76 | $1.31 | $1.32 | −$16.70 | — | −$9.48 | −$5.41 | −$1.40 |
| Cash per share | $34.27 | $51.94 | $79.44 | $76.52 | — | $5.53 | $4.55 | — |
| Book value per share | $9.00 | $7.27 | $9.02 | $22.50 | — | −$17.47 | −$0.75 | — |
| Tangible book value per share | −$14.92 | −$16.73 | −$19.52 | −$0.53 | — | −$104.64 | −$99.59 | — |
| Dividends per share | — | — | — | — | — | $0.19 | $0.00 | $15.74 |
| Capex per share | $0.76 | $0.95 | $1.98 | $2.34 | — | $2.23 | $6.49 | $1.26 |
| Debt per share | $55.77 | $79.75 | $114.26 | $101.25 | — | $126.28 | $118.37 | — |
| Shares outstanding | 6.8M | 7.1M | 6.6M | 7.4M | — | 1.7M | 1.6M | 6.3M |
| Change in shares outstanding | −4.7% | +8.2% | −11.3% | — | — | +6.7% | −74.4% | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | −16.9% | −52.3% | −88.4% | 18.8% | −278.2% | — | — | — |
| Return on invested capital (ROIC) | −7.2% | −19.9% | −32.4% | −10.4% | −20.3% | −7.6% | 5.9% | — |
| Return on assets (ROA) | −1.6% | −3.6% | −10.4% | 4.0% | −52.5% | −13.0% | −0.7% | — |
| Return on tangible assets | −2.8% | −5.7% | −13.5% | 5.3% | −36.5% | −39.8% | −2.4% | — |
| Free cash flow margin | 10.7% | 2.8% | 2.2% | −33.9% | −16.9% | −13.6% | −5.2% | −7.8% |
| Income quality (OCF / net income) | — | — | — | −2.41 | — | — | — | — |
| Financial health | ||||||||
| Total debt | $378.7M | $568.2M | $752.3M | $751.8M | $733.6M | $216.5M | $190.2M | — |
| Cash & short-term investments | $232.7M | $370.1M | $523.0M | $568.2M | $901.9M | $9.5M | $7.3M | — |
| Net debt | $146.0M | $198.1M | $229.3M | $183.6M | −$168.3M | $207.1M | $182.9M | — |
| Debt / equity | 6.20 | 10.97 | 12.67 | 4.50 | 2.43 | — | — | — |
| Debt / assets | 0.76 | 0.83 | 0.81 | 0.75 | 0.60 | 0.97 | 0.84 | — |
| Net debt / EBITDA | 3.77 | 13.62 | — | 2.25 | — | — | 6.51 | — |
| Current ratio | 1.66 | 7.00 | 6.07 | 10.92 | 13.09 | 1.91 | 1.43 | — |
| Quick ratio | 1.40 | 5.99 | 5.28 | 9.39 | 12.63 | 1.16 | 0.92 | — |
| Interest coverage | -1.1 | -6.5 | -9.6 | -1.9 | -3.4 | -0.8 | 0.8 | 1.0 |
| Working capital | $123.2M | $409.0M | $583.2M | $711.6M | $924.5M | $28.2M | $16.4M | — |
| Invested capital | $207.1M | $249.9M | $288.7M | $350.6M | $134.0M | $177.1M | $181.7M | — |
| Tangible asset value | −$101.3M | −$119.2M | −$128.6M | −$3.9M | $122.6M | −$179.4M | −$160.0M | — |
| Net current asset value | −$129.2M | −$156.8M | −$171.5M | −$52.8M | $84.4M | −$193.7M | −$173.4M | — |
| Graham number | — | — | — | $54.91 | — | — | — | — |
| Graham net-net per share | −$24.22 | −$29.18 | −$39.45 | −$20.83 | — | −$124.99 | −$119.96 | — |
| Capital allocation | ||||||||
| Dividends paid | — | — | — | — | — | $323,000 | $0 | $98.7M |
| Share buybacks (net) | $0 | $2.0M | $32.4M | $160.0M | $0 | $154,000 | $0 | $0 |
| Dividends + buybacks / free cash flow | 0.0% | 21.0% | 372.3% | — | — | — | — | — |
| Capex / revenue | 1.7% | 2.0% | 3.3% | 4.8% | 6.0% | 3.2% | 6.3% | 7.0% |
| Capex / operating cash flow | 13.8% | 42.1% | 60.0% | — | — | — | 603.1% | — |
| Capex / depreciation | 0.20 | 0.20 | 0.38 | 0.76 | 0.87 | 0.26 | 0.75 | 0.69 |
| Stock-based compensation / revenue | 4.9% | 8.0% | 5.7% | 7.8% | 4.8% | 0.3% | 0.1% | 0.1% |
| R&D / revenue | 1.9% | 1.9% | 2.5% | 2.3% | 3.2% | 2.9% | 2.8% | 2.1% |
| SG&A / revenue | 70.3% | 72.9% | 69.3% | 72.8% | 80.8% | 68.0% | 53.1% | 53.9% |
| Efficiency | ||||||||
| Days sales outstanding | 31.5 | 45.6 | 60.9 | 64.4 | 52.4 | 71.9 | 52.0 | — |
| Days of inventory on hand | 204.7 | 192.6 | 151.0 | 225.9 | 130.8 | 149.9 | 118.0 | — |
| Days payables outstanding | 65.6 | 80.1 | 55.0 | 89.6 | 106.4 | 115.1 | 86.6 | — |
| Cash conversion cycle (days) | 170.6 | 158.1 | 156.9 | 200.7 | 76.8 | 106.7 | 83.4 | — |
| Receivables turnover | 11.59 | 8.01 | 5.99 | 5.66 | 6.97 | 5.08 | 7.02 | — |
| Payables turnover | 5.56 | 4.56 | 6.63 | 4.07 | 3.43 | 3.17 | 4.22 | — |
| Inventory turnover | 1.78 | 1.89 | 2.42 | 1.62 | 2.79 | 2.43 | 3.09 | — |
| Asset turnover | 0.51 | 0.41 | 0.41 | 0.33 | 0.36 | 0.53 | 0.74 | — |
| Average receivables | $25.9M | $41.7M | $66.4M | $64.6M | $37.3M | $23.5M | $23.7M | — |
| Average payables | $18.8M | $33.4M | $36.6M | $28.8M | $23.8M | $16.4M | $14.3M | — |
| Average inventory | $58.6M | $80.2M | $100.5M | $72.5M | $29.2M | $21.3M | $19.4M | — |
| Intangibles / total assets | 32.5% | 24.9% | 20.2% | 17.0% | 14.7% | 67.1% | 70.2% | — |
Computed from SKIN's annual financial statements (latest annual report filed March 12, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
SKIN valuation and financial ratios
Beauty Health earned a return on equity of −16.9% and a return on invested capital of −7.2% in fiscal 2025. It ended the year with $378.7 million of debt and $232.7 million in cash and short-term investments, net debt of $146.0 million. The share count rose 8.3% from 6.3M to 6.8M over 7 years.
See the SKIN income statement, the SKIN chart for price history, or the SKIN stock overview for the latest quote and news.
SKIN key metrics FAQ
What is Beauty Health's EV/EBITDA?
Beauty Health's enterprise value was 8.6 times EBITDA at the end of fiscal 2025 (enterprise value $334.8 million, EBITDA $38.7 million); the current EV/EBITDA is 9.6.
What is Beauty Health's return on equity?
Beauty Health's return on equity (ROE) was −16.9% in fiscal 2025: net income of -$9.5 million on average shareholders' equity of $56.5 million.
What is Beauty Health's ROIC?
Beauty Health's return on invested capital was −7.2% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Beauty Health have?
Beauty Health had total debt of $378.7 million at the end of fiscal 2025, a debt-to-equity ratio of 6.20 and $146.0 million of net debt (3.77 times EBITDA).
What is Beauty Health's free cash flow yield?
Beauty Health generated $32.3 million of free cash flow in fiscal 2025, a free cash flow yield of 17.1% on its market value at year-end ($188.8 million).
What is Beauty Health's current ratio?
Beauty Health's current ratio was 1.66 at the end of fiscal 2025: current assets were 1.66 times current liabilities.